Form 4: CG Oncology Director Leonard Post Executes Stock Option and Sells Shares
SEC Form 4 Filing
Director Leonard Post exercised stock options and sold shares of CG Oncology under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On February 18, 2025, Leonard Post, a director of CG Oncology, exercised a stock option to acquire 1,000 shares of common stock at a price of $0.60 per share.
- Simultaneously, Post sold 1,000 shares of CG Oncology common stock at a price of $28.61 per share.
- The sale was executed under a Rule 10b5-1 trading plan adopted on September 6, 2024.
- Following these transactions, Post directly owns 0 shares of common stock and 131,077 derivative securities.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it reports routine insider trading activity under a pre-arranged plan. There is no indication of positive or negative implications for the company.
Industry Context
This filing is a routine disclosure of insider trading activity. It is common for executives and directors to utilize Rule 10b5-1 trading plans to sell shares over time to avoid accusations of insider trading.
Key Dates
| Date | Description |
|---|---|
| 09/06/2024 | Date of adoption of Rule 10b5-1 trading plan |
| 02/18/2025 | Date of stock option exercise and share sale |
| 02/19/2025 | Date of signature of the Form 4 filing |
| 07/08/2028 | Expiration date of Director Stock Option |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.